Watertown, Mass. — November 4, 2025 — Leads & Copy —
Kymera Therapeutics, Inc. (NASDAQ: KYMR) has completed enrollment and dosing in the KT-621 BroADen Phase 1b trial for atopic dermatitis (AD) patients, with data expected in December 2025. The KT-621 BROADEN2 Phase 2b trial in AD has been initiated, and the KT-621 BREADTH Phase 2b trial in asthma is on track to start in 1Q26. IND-enabling studies for KT-579 (IRF5) are complete, with a Phase 1 clinical trial anticipated in early 2026. As of September 30, 2025, Kymera is well-capitalized with $979 million in cash, providing a runway into the second half of 2028. The company will host a video conference call and webcast today at 8:30 a.m. ET.
Kymera’s CEO, Nello Mainolfi, PhD, highlighted the team’s progress and anticipates important milestones in the fourth quarter and early next year.
KT-621, a first-in-class oral STAT6 degrader, showed complete STAT6 degradation, reduced Type 2 biomarkers, and a safety profile similar to placebo in a Phase 1 study.
KT-579, an oral IRF5 degrader, could selectively block inflammation and restore immune regulation. Preclinical studies showed KT-579 degraded IRF5 and was effective in models of lupus and rheumatoid arthritis.
KT-485/SAR447971, in partnership with Sanofi, is in IND-enabling studies for immuno-inflammatory diseases, with clinical entry expected in 2026.
Preclinical activities are ongoing under an exclusive option and license agreement with Gilead Sciences to advance the Company’s CDK2 molecular glue program for the potential treatment of breast cancer and solid tumors.
Third-quarter financial results include collaboration revenues of $2.8 million, research and development expenses of $74.1 million, and a net loss of $82.2 million.
Contact: Justine Koenigsberg, Vice President, Investor Relations, investors@kymeratx.com, media@kymeratx.com, 857-285-5300
Source: Kymera Therapeutics, Inc.
